Recombinant Human B7-H2 Fc Chimera Avi-tag Protein, CF

When Recombinant Human ICOS Fc Chimera Protein (169-CS) is immobilized at 0.5 μg/mL (100 μL/well), Biotinylated Recombinant Human B7-H2 Fc Chimera Avi-tag (AVI165) that produces a 50% optimal binding response is found to be 1-6 ng/mL.

2 μg/lane of Recombinant Human B7-H2 Fc Chimera Avi-tag Protein (AVI165) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 80-100 kDa and 160-200 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human B7-H2 Fc Chimera Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: The biotin to protein ratio is 0.7 as determined by the HABA assay. Measured by its binding ability in a functional ELISA. When Recombinant Human ICOS Fc Chimera Protein (Catalog # 169-CS) is immobilized at 0.5 µg/mL (100 µL/ well), Biotinylated Recombinant Human B7‑H2 Fc Chimera Avi-tag (Catalog # AVI165) that produces a 50% optimal binding response is found to be 1-6 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human B7-H2 protein
  

  Human B7-H2 (Asp19-Ser258) Accession # O75144.2	DIEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: O75144.1
• N-terminal Sequence: Asp19
• Structure / Form: Disulfide-linked homodimer, biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 55 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 80-100 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human B7-H2 Fc Chimera Avi-tag Protein, CF

• B7H2
• B7-H2
• B7H2B7 homolog 2
• B7-H2B7-related protein 1
• B7RP-1
• B7RP1B7-like protein Gl50
• B7RP-1LICOS
• CD275 antigen
• CD275
• GL50
• GL50transmembrane protein B7-H2 ICOS ligand
• ICOSL
• ICOS-L
• ICOSLG
• inducible T-cell co-stimulator ligand
• KIAA0653ICOS ligand

Background

B7-H2, also known as B7-related protein (B7RP1), ICOS Ligand, and CD275, is transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H2 consists of an extracellular domain (ECD) with two immunoglobulin-like domains, a transmembrane segment, and a short cytoplasmic domain (2, 3). Alternative splicing generates a long isoform that carries a 10 amino acid (aa) substitution for the C-terminal 3 residues. Within the ECD, human B7-H2 shares 50% and 54% aa sequence identity with mouse and rat B7‑H2, respectively. B7-H2 is expressed on antigen presenting cells such as B cells, macrophages, monocytes, and dendritic cells (2-6). It binds to ICOS on activated T cells, leading to both positive and negative effects on immune responses including its own down-regulation (2, 4, 7). Mouse and human B7-H2 exhibit cross-species binding to ICOS (3, 6). The B7-H2 interaction with ICOS is co-stimulatory for T cell proliferation as well as the development of B cells, plasma cells, follicular helper T cells (Tfh) and germinal centers (2-4, 8, 9). In human but not in mouse, B7-H2 additionally binds to CD28 and CTLA4, and its interaction with CD28 can co-stimulate both human and mouse naïve T cells and regulatory T cells (Treg) (6). B7-H2 contributes to the development of allergic asthma by enhancing Th2 biased immune responses, limiting Th17 responses, and promoting eosinophilic infiltration into the lung (8, 10, 11). Its activation of ICOS on Treg limits pulmonary inflammation and airway hyperresponsiveness, promotes the development of inhalational tolerance, and impairs anti-tumor immunity (5, 12, 13). In contrast, its ligation of ICOS on Tfh cells can increase the severity of autoimmune symptoms (9). A soluble form of human B7-H2 is elevated in the circulation of patients with active systemic lupus erythematosus (14).In the thyroid, B7-H2 is up-regulated on thyrocytes during inflammation and promotes their proliferation and production of thryoid hormones (15). Our Avi-tag Biotinylated Recombinant Human B7-H2 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
2. Wang, S. et al. (2000) Blood 96:2808.
3. Yoshinaga, S.K. et al. (2000) Int. Immunol. 12:1439.
4. Yoshinaga, S.K. et al. (1999) Nature 402:827.
5. Faget, J. et al. (2012) Cancer Res. 72:6130.
6. Yao, S. et al. (2011) Immunity 32:729.
7. Watanabe, M. et al. (2008) J. Immunol. 180:5222.
8. Wong, S.-C. et al. (2003) Blood 102:1381.
9. Hu, Y.-L. et al. (2009) J. Immunol. 182:1421.
10. Kadkhoda, K. et al. (2010) J. Immunol. 184:3780.
11. Kadkhoda, K. et al. (2011) Int. Immunol. 23:239.
12. Gajewska, B.U. et al. (2005) J. Immunol. 174:3000.
13. Akbari, O. et al. (2002) Nat. Med. 8:1024.
14. Her, M. et al. (2009) Lupus 18:501.
15. Wang, F. et al. (2012) J. Clin. Immunol. 32:1253.

Bioinformatics

• Uniprot:
  • O75144.1()